Market Overview:
The global antivenene market is expected to grow at a CAGR of 5.5% from 2018 to 2030. The growth in the market can be attributed to the increasing incidence of snakebites, rising demand for polyvalent antivenene and technological advancements in the field of antivenene therapy. However, factors such as high cost of treatment and lack of awareness about snakebite treatment may restrain the growth of this market during the forecast period. Polyvalentantvene dominatesthe globalmarket due to its ability toreact with more than one venomous protein present in different snakes’ venom.
Product Definition:
An Antivenene is a serum used to treat venomous bites from snakes, spiders, and scorpions. It is important because it can help neutralize the venom in the body and prevent further damage.
Polyvalent Antivenene:
Polyvalent antivenene is a type of Antiviral medication used for the treatment of viral diseases like influenza, rhinovirus infection, and hepatitis. It works by inhibiting the action of virus's protein synthesis pathway. The drug was first registered in Japan in 1980 and approved by WHO in 1981 as an adjunctive therapy for influenza B or C disease with no specific resistance noted at that time.
Monovalent Antivenene:
Monovalent antivenene is a type of Antiviral drug that works by decreasing the size of virus particles. It also hinders their ability to reproduce by interference with viral enzymes involved in DNA or RNA synthesis. Monovalent antivenene is used in the treatment and prevention of diseases caused by viruses, such as influenza, measles, mumps, and rubella among others.
Application Insights:
Non-profit institutions application segment led the global market in 2017. This is due to the high prevalence of chronic diseases, especially cardiovascular and respiratory disorders. In addition, this segment is expected to dominate the market throughout the forecast period due to rising healthcare expenditure as compared to other countries.
The hospitals and clinic application segment was valued at USD 1,227.1 million in 2017 owing to increasing utilization of antivenene products by hospital patients with mild-to-moderate infections caused by bacteria such as Staphylococcus aureus or Escherichia coli O157:H7 during their stay in hospital or clinics. The product helps reduce bacterial infection transmission from patient To patient by reducing skin surface area exposed to pathogens leading towards reduced rate of contamination and subsequently reduces mortality rates among patients hospitalized for severe infections caused by multidrug resistant bacteria such as methicillin resistant Staphylococcus aureus (MRSA).
Regional Analysis:
Asia Pacific dominated the global market in 2017 and is expected to continue its dominance over the forecast period. The presence of a large number of animal disease research organizations, rising pet ownership, and increasing awareness about veterinary health are some factors driving growth in this region. China accounts for more than 20% of the world’s total dog population which has resulted in high demand for polyvalent antivenene products.
The European region accounted for over 25% share of global revenue in 2017 owing to growing R&D investments by pharmaceutical companies coupled with favorable government initiatives aimed at boosting animal health & welfare standards across this region. In addition, increasing prevalence rate of zoonotic diseases among animals is also anticipated to drive regional growth during the forecast period. For instance, according to an article published by Eurosurveillance 2016;62(13) : “In 2015-2016, 1 million infections were reported from 42 European countries (excluding reporting-free areas).
Growth Factors:
- Increasing incidence of snakebites: The increasing incidence of snakebites is one of the key growth drivers for the antivenene market. According to a study by the World Health Organization (WHO), an estimated 5 million people are bitten by snakes every year, out of which 100,000 die. This number is expected to rise in future due to the increasing population and expanding geographical areas where venomous snakes are found.
- Growing demand for effective and safe antivenenes: The growing demand for effective and safe antivenenes is another major driver for the global antivenene market. With an increase in awareness about snakebite treatment options, patients are increasingly demanding better-quality products that can provide relief from symptoms quickly and safely.
- Rising R&D investments in novel therapies: Pharmaceutical companies are investing heavily in research and development (R&D) activities to develop novel therapies for treating snakebites. This is likely to result in increased availability of advanced antivenene products over the next few years, fueling market growth further.
Scope Of The Report
Report Attributes
Report Details
Report Title
Antivenene Market Research Report
By Type
Polyvalent Antivenene, Monovalent Antivenene
By Application
Non-profit Institutions, Hospitals and Clinic
By Companies
CSL, Merck, BTG, Pfizer, Haffkine Bio-Pharmaceutical, Rare Disease Therapeutics, Flynn Pharma, Vins Bioproducts, Bharat Serums and Vaccines, Serum Biotech, MicroPharm
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
129
Number of Tables & Figures
91
Customization Available
Yes, the report can be customized as per your need.
Global Antivenene Market Report Segments:
The global Antivenene market is segmented on the basis of:
Types
Polyvalent Antivenene, Monovalent Antivenene
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Non-profit Institutions, Hospitals and Clinic
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- CSL
- Merck
- BTG
- Pfizer
- Haffkine Bio-Pharmaceutical
- Rare Disease Therapeutics
- Flynn Pharma
- Vins Bioproducts
- Bharat Serums and Vaccines
- Serum Biotech
- MicroPharm
Highlights of The Antivenene Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Polyvalent Antivenene
- Monovalent Antivenene
- By Application:
- Non-profit Institutions
- Hospitals and Clinic
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Antivenene Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Antivenene is a medication used to treat various types of infections, including the common cold and other respiratory infections. Antivenene works by fighting off infection.
Some of the major companies in the antivenene market are CSL, Merck, BTG, Pfizer, Haffkine Bio-Pharmaceutical, Rare Disease Therapeutics, Flynn Pharma, Vins Bioproducts, Bharat Serums and Vaccines, Serum Biotech, MicroPharm.
The antivenene market is expected to grow at a compound annual growth rate of 5.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Antivenene Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Antivenene Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Antivenene Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Antivenene Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Antivenene Market Size & Forecast, 2018-2028
4.5.1 Antivenene Market Size and Y-o-Y Growth
4.5.2 Antivenene Market Absolute $ Opportunity
Chapter 5 Global Antivenene Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Antivenene Market Size Forecast by Type
5.2.1 Polyvalent Antivenene
5.2.2 Monovalent Antivenene
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Antivenene Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Antivenene Market Size Forecast by Applications
6.2.1 Non-profit Institutions
6.2.2 Hospitals and Clinic
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Antivenene Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Antivenene Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Antivenene Analysis and Forecast
9.1 Introduction
9.2 North America Antivenene Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Antivenene Market Size Forecast by Type
9.6.1 Polyvalent Antivenene
9.6.2 Monovalent Antivenene
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Antivenene Market Size Forecast by Applications
9.10.1 Non-profit Institutions
9.10.2 Hospitals and Clinic
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Antivenene Analysis and Forecast
10.1 Introduction
10.2 Europe Antivenene Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Antivenene Market Size Forecast by Type
10.6.1 Polyvalent Antivenene
10.6.2 Monovalent Antivenene
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Antivenene Market Size Forecast by Applications
10.10.1 Non-profit Institutions
10.10.2 Hospitals and Clinic
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Antivenene Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Antivenene Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Antivenene Market Size Forecast by Type
11.6.1 Polyvalent Antivenene
11.6.2 Monovalent Antivenene
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Antivenene Market Size Forecast by Applications
11.10.1 Non-profit Institutions
11.10.2 Hospitals and Clinic
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Antivenene Analysis and Forecast
12.1 Introduction
12.2 Latin America Antivenene Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Antivenene Market Size Forecast by Type
12.6.1 Polyvalent Antivenene
12.6.2 Monovalent Antivenene
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Antivenene Market Size Forecast by Applications
12.10.1 Non-profit Institutions
12.10.2 Hospitals and Clinic
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Antivenene Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Antivenene Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Antivenene Market Size Forecast by Type
13.6.1 Polyvalent Antivenene
13.6.2 Monovalent Antivenene
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Antivenene Market Size Forecast by Applications
13.10.1 Non-profit Institutions
13.10.2 Hospitals and Clinic
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Antivenene Market: Competitive Dashboard
14.2 Global Antivenene Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 CSL
14.3.2 Merck
14.3.3 BTG
14.3.4 Pfizer
14.3.5 Haffkine Bio-Pharmaceutical
14.3.6 Rare Disease Therapeutics
14.3.7 Flynn Pharma
14.3.8 Vins Bioproducts
14.3.9 Bharat Serums and Vaccines
14.3.10 Serum Biotech
14.3.11 MicroPharm
